LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
LBH589 is an oral drug that targets the myelofibrosis cells in the bone marrow and induces
cell death by allowing for the expression of certain suppressed genes that are important in
regulating cell survival. Based on laboratory studies, the hypothesis is that this drug will
selectively kill the stem cells responsible for causing myelofibrosis and result in reduction
in spleen size and ultimately restoration of normal bone marrow function.